This is an open-label, multi-center, roll-over study to evaluate the long term safety of
ribociclib in combination with other drugs in participants who are participating in a
Novartis sponsored global study, that has fulfilled requirements for its primary
objective(s), and who in the opinion of the Investigator, would benefit from continued
treatment.
Additional locations may be listed on ClinicalTrials.gov for NCT05161195.
Locations matching your search criteria
United States
Ohio
Cleveland
Case Comprehensive Cancer CenterStatus: Active
Name Not Available
The purpose of this study is to evaluate long-term safety and provide continued treatment
to participants who are currently receiving ribociclib in combination with other drugs in
a parent study, that has fulfilled requirements for its primary objective(s), and in the
opinion of the Investigator, would benefit from continuing treatment at time of
discontinuation from the parent study
Lead OrganizationNovartis Pharmaceuticals Corporation
